Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsLaxmicotspin

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Lupin Q1 Preview: Healthy US sales, favourable base to lift earnings

      Easing headwinds which dragged Lupin's financials in the base quarter, along with healthy sales in the US are likely to lift financials for the drugmaker in Q1.

    • Lupin Q1 PAT may dip 73.3% YoY to Rs 144.7 cr: ICICI Direct

      Net Sales are expected to decrease by 6.2 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs 4,007.1 crore, according to ICICI Direct.

    • Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher

      Net Sales are expected to decrease by 0.7 percent Y-o-Y (up 9.2 percent Q-o-Q) to Rs 4,240.2 crore, according to Prabhudas Lilladher.

    • Lupin Q4 PAT may dip 49.9% YoY to Rs 230.5 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 6.3 percent Y-o-Y (down 3.3 percent Q-o-Q) to Rs 4,021.7 crore, according to Prabhudas Lilladher.

    • Lupin Q2 PAT seen up 33.1% YoY to Rs 280.9 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 0.6 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs 3,802.8 crore, according to Prabhudas Lilladher.

    • Lupin Q1 PAT seen up 258.7% YoY to Rs 389.9 cr: KRChoksey

      Net Sales are expected to increase by 17 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs 4,127.6 crore, according to KRChoksey.

    • Lupin Q1 PAT seen up 474% YoY to Rs 613.6 cr: ICICI Direct

      Net Sales are expected to increase by 20.6 percent Y-o-Y (up 12.5 percent Q-o-Q) to Rs 4,256 crore, according to ICICI Direct.

    • LUPIN Q4 PAT seen up 3.5% YoY to Rs. 317.2 cr: Sharekhan

      Net Sales are expected to increase by 3.5 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs. 3,979 crore, according to Sharekhan.

    • Lupin Q2 Preview: Adjusted profit may decline sharply on subdued revenue, operating performance

      Guidance for launches and traction in the US in the second half of FY21 and update on albuterol market share after its launch in the American market would be key things to watch out for.

    • Lupin Q4 FY20 results: Key highlights of concall

      The company expects specialty portfolio to breakeven in FY22.

    • Lupin Q4 preview: Double-digit decline seen in profit, revenue

      Motilal Oswal feels domestic formulation business is expected to drive revenue growth, but US sales may decline 10 percent YoY.

    • Lupin widens losses in Q3; highlights of conference call

      The company expects to launch more than 15 products in US in FY21.

    • Lupin Q2 preview: Profit may grow in double-digits on better operating income

      Motilal Oswal expects EBITDA margin to grow 470 bps to 18.6 percent YoY on account of superior product mix and better operating leverage

    • Lupin Q2 PAT may dip 22% YoY to Rs. 206.5 cr: Emkay

      Net Sales are expected to increase by 6.2 percent Y-o-Y (down 5.1 percent Q-o-Q) to Rs. 4,195.2 crore, according to Emkay.

    • Lupin Q1 PAT seen up 17.6% YoY to Rs. 296.5 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 14.6 percent Y-o-Y to Rs. 4,324.2 crore, according to Prabhudas Lilladher.

    • Lupin Q4 preview: Net profit likely to fall, EBITDA margin to take a hit

      Narnolia expects EBITDA margin to decline by 171 bps YoY to 15.9 percent in Q4FY19 on account of increased remediation cost related to inspection in Somerset and Mandideep facilities.

    • Lupin Q4 PAT may dip 62.8% YoY to Rs. 253.2 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 2.1 percent Y-o-Y (down 7.2 percent Q-o-Q) to Rs. 4,061 crore, according to Prabhudas Lilladher.

    • Lupin Q3 PAT seen up 20.7% YoY to Rs. 267.1 cr: ICICI Direct

      Net Sales are expected to increase by 0.4 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 3,991 crore, according to ICICI Direct.

    • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

      For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

    • Lupin Q2 preview: Weakness in US business to hurt, say experts

      Resolution of the warning letter at Lupin's Goa and Indore sites is also the key event to watch out for in second half of FY19.

    • Lupin Q2 PAT may dip 59.1% YoY to Rs. 190 cr: HDFC Securities

      Net Sales are expected to decrease by 2.9 percent Y-o-Y (down 0.4 percent Q-o-Q) to Rs. 3,840 crore, according to HDFC Securities.

    • Lupin Q2 PAT may dip 34% YoY to Rs. 299 cr: Sharekhan

      Net Sales are expected to increase by 0.4 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 3,969 crore, according to Sharekhan.

    • Lupin Q2 PAT may dip 51.2% YoY to Rs. 222.2 cr: ICICI Direct

      Net Sales are expected to increase by 2 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs. 4,032.1 crore, according to ICICI Direct.

    • Lupin Q1 PAT may dip 2.9% YoY to Rs. 347.5 cr: Kotak

      Net Sales are expected to increase by 6.1 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,104.2 crore, according to Kotak.

    • Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

      "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347